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Abstract The Genetics Core of the Alzheimer’s Disease
Neuroimaging Initiative (ADNI), formally established in
2009, aims to provide resources and facilitate research related
to genetic predictors of multidimensional Alzheimer’sd i s e a s e
(AD)-related phenotypes. Here, we provide a systematic
review of genetic studies published between 2009 and 2012
where either ADNI APOE genotype or genome-wide associ-
ation study (GWAS) data were used. We review and synthe-
size ADNI genetic associations with disease status or quanti-
tative disease endophenotypes including structural and
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DOI 10.1007/s11682-013-9262-zfunctional neuroimaging, fluid biomarker assays, and cogni-
tive performance. We also discuss the diverse analytical strat-
egies used in these studies, including univariate and multivar-
iate analysis, meta-analysis, pathway analysis, and interaction
and network analysis. Finally, we perform pathway and net-
work enrichment analyses of these ADNI genetic associations
to highlight key mechanisms that may drive disease onset and
trajectory. Major ADNI findings included all the top 10 AD
genes and several of these (e.g., APOE, BIN1, CLU, CR1,
andPICALM) were corroborated by ADNI imaging, fluid and
cognitive phenotypes.ADNIimaginggeneticsstudies discov-
ered novel findings (e.g., FRMD6) that were later replicated
ondifferentdatasets.Several othergenes (e.g.,APOC1, FTO,
GRIN2B, MAGI2, and TOMM40) were associated with mul-
tiple ADNI phenotypes, warranting further investigation on
other data sets. The broad availability and wide scope of
ADNI genetic and phenotypic data has advanced our under-
standing of the genetic basis of AD and has nominated novel
targets for future studies employing next-generation sequenc-
ing and convergent multi-omics approaches, and for clinical
drug and biomarker development.
Keywords Alzheimer’sdi se ase.Geneticassociationstudy .
Quantitativetraits .Neuroimaging .Biomarker .Cognition
Introduction
The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
was launched in 2003 by the National Institute on Aging
(NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration
(FDA), private pharmaceutical companies and non-profit or-
ganizations, as a $60 million, 5-year public–private partner-
ship (Weiner et al. 2012). The primary goal of ADNI has been
to test whether serial magnetic resonance imaging (MRI),
positron emission tomography (PET), other biological
markers, and clinical and neuropsychological assessment can
be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD).
Determination of sensitive and specific markers of very early
AD progression is intended to aid researchers and clinicians
with developing new treatments and monitoring their effec-
tiveness, as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W.
Weiner, MD, VA Medical Center and University of California
– San Francisco. ADNI is the result of efforts of many co-
investigators from a broad range of academic institutions and
private corporations, and participants have been recruited
from over 50 sites across the U.S. and Canada. The initial
goal of ADNI was to recruit and clinically monitor 800
participants but this initial study (i.e., ADNI-1) has been
followed by additional funding and additional iterations,
known as ADNI-GO and ADNI-2. To date, these three pro-
tocols have recruited over 1,500 adults, ages 55 to 90, to
participate in the research, consisting of cognitively normal
older individuals, people with significant memory concerns,
people with early or late MCI, and people with early AD.
The follow up duration for each group is specified in the
ADNI-1, ADNI-GO and ADNI-2 protocols. Participants
originally recruited for ADNI-1 and ADNI-GO had the
option to be followed in ADNI-2. For up-to-date informa-
tion, see www.adni-info.org.
The ADNI Genetics Core (Saykin et al. 2010), formally
established in 2009, aims to provide genetic resources and
facilitate genetics research related to ADNI multidimensional
phenotypes. As of June 9, 2013, the available ADNI genetics
data include the APOE genotyping data for 1,909 participants
(818 ADNI-1 participants, 341 additional ADNI-1 partici-
pants who failed screening, and 750 ADNI-GO/2 partici-
pants), and Genome Wide Association Study (GWAS) data
for 1,252 participants. The GWAS data was collected from
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184 Brain Imaging and Behavior (2014) 8:183–207818 DNA samples of ADNI-1 participants using Illumina
Human 610-Quad genotyping array, and from 434 DNA
samples of ADNI-GO/2 participants using Illumina
OmniExpress genotyping array.
In this paper, we review the ADNI genetic studies pub-
lished between 2009 and 2012, where either ADNI APOE or
GWAS data have been used. We searched the PubMed data-
base using the EndNote X4 online search tool with the fol-
lowing three criteria: (1) The “Author”, “Title”, “Abstract” or
“Keywords” field contains “ADNI” or “Alzheimer’sD i s e a s e
Neuroimaging Initiative”;( 2 )T h e“Title”, “Abstract” or
“Keywords” field contains “APOE”, “apolipoprotein”,
“gene”, “genetic”, “genetics”, “genotyping”, “genome”, “ge-
nomic”,o r“genomics”;a n d( 3 )T h e“Year” field value is
between 2009 and 2012. We integrated the search results with
the ADNI publication database maintained by the ADNI Data
and Publications Committee (DPC). We manually reviewed
all the abstracts and identified 106 relevant ADNI genetics
publications through this extensive search. The number of
publications (Fig. 1) grew from 3 in 2009,
1 to 23 in 2010,
2
28 in 2011,
3 and 52 in 2012.
4
Amongthese,30papersanalyzedonlyAPOE,and76used
the GWAS data. Table 1 shows a high level classification of
these papers based on different genotype, phenotype, and
method categories. In particular, rich multidimensional
ADNI phenotypes have facilitated a range of quantitative trait
(QT) analyses, including structural imaging (N=55), func-
tional imaging (N=15, including functional MRI and PET),
biofluids (N=24), and cognition (N= 2 2 ) ,i na d d i t i o nt oc a s e
control analyses (N=26). The availability of ADNI genetic
and multimodal phenotypic data led to numerous research
findings that demonstrate the power of multidimensional
quantitative phenotype data for identifying novel genetic var-
iants. For example, as reported in Saykin et al. (2012), the
FRMD6 gene (Fig. 2) was identified in three ADNI imaging
genetics studies (Furney et al. 2011; Potkin et al. 2009a;S t e i n
et al. 2010a)( N≤1,004) and later validated by a case control
GWAS with a much larger sample (Hong et al. 2012)( N>12,
500). This clearly illustrates the statistical power of QT
analyses.
Binary versus quantitative phenotypes
Case control analysis
ADNIdatahasbeeninvestigatedaloneorincombinationwith
other cohorts, such as those in the Alzheimer’sD i s e a s e
Genetics Consortium (ADGC, http://alois.med.upenn.edu/
adgc/), in numerous case control analyses including both
candidate gene and GWAS studies. The following highlights
a few case control studies that examined ADNI data alone:
Potkin et al. (2009a) performed a GWAS and identified APOE
and TOMM40 loci at a significance level of p≤10
−6;B i f f i
et al. (2010) focused on a few candidate single nucleotide
polymorphisms (SNPs) and confirmed the APOE locus as
associated with Alzheimer’s disease in the ADNI cohort; and
Lakatos et al. (2010) studied mitochondral haplogroups and
SNPs and reported that a mitochondrial haplogroup (UK)
might confer genetic susceptibility to AD independent of the
APOE ε4 allele. Many more studies combined ADNI with
other cohorts, performed candidate gene/GWAS and meta-
analyses. These studies nominated or confirmed multiple
AD susceptibility loci, including: CR1, CLU and PICALM
(Jun et al. 2010), epistatic interaction between TF and HFE
(Kauweetal.2010a),APOE andMTHFD1L (Najetal.2010),
CR1 (Antunez et al. 2011b), MS4A gene cluster (Antunez
et al. 2011a), ABCA7, MS4A6A/MS4A4E, EPHA1, CD33
and CD2AP (Hollingworth et al. 2011), BIN1 (Hu et al.
2011a), MS4A4/MS4A6E, CD2AP, CD33 and EPHA (Naj
et al. 2011). Some studies also discovered suggestive novel
associations in PPP1R3B (Kamboh et al. 2012)a n dFTO
(Reitz et al. 2012).
Quantitative phenotype analysis
Given the very rich multimodal quantitative phenotype
data available in ADNI, many QT studies have been
performed in addition to the case control analyses men-
tioned above (Table 1). The QT approach has distinct
advantages in power over categorical diagnoses (i.e.,
1 (Langbaum et al. 2009; Potkin et al. 2009a; Schuff et al. 2009)
2 (Apostolova et al. 2010; Biffi et al. 2010; Caroli and Frisoni 2010;
Cruchaga et al.2010; Fan etal. 2010; Hanetal. 2010;H oe ta l .2010;J u n
et al. 2010; Kauwe et al. 2010a, b; Lakatos et al. 2010; Naj et al. 2010;
Rimol et al. 2010;R i s a c h e re ta l .2010; Saykin et al. 2010;S h e ne ta l .
2010; Stein et al. 2010a, b; Tosun etal. 2010;V e m u r ie ta l .2010; Vounou
et al. 2010; Wolk and Dickerson 2010;X ue ta l .2010)
3 (Alexopoulos et al. 2011; Antunez et al. 2011a, b;B a k k e ne ta l .2011;
Cruchaga et al. 2011; David et al. 2011; Dickerson and Wolk 2011;
Furney et al. 2011; Hibar et al. 2011a, b, c; Hollingworth et al. 2011;
Hu et al. 2011a, b;K a m b o he ta l .2011; Kauwe et al. 2011; Kim et al.
2011; Kohannim et al. 2011; Naj et al. 2011; Nho et al. 2011;O ’Bryant
et al. 2011;S i l v e re ta l .2011; Spiegel et al. 2011; Stein et al. 2011;
Swaminathan et al. 2011; Tosun et al. 2011; Wan et al. 2011; Yesavage
et al. 2011)
4 (Andrawis et al. 2012;B a k k e ne ta l .2012; Bis et al. 2012; Bonner-
Jackson et al. 2012;C r u c h a g ae ta l .2012; Damoiseaux et al. 2012;D e
Jageretal.2012;Desikanetal.2012;Geetal .2012;Hibaretal.2012;H u
et al. 2012;J a c ke ta l .2012; Jagust and Landau 2012; Jahanshad et al.
2012; Kamboh et al. 2012; Keenan et al. 2012; Kiddle et al. 2012;
Kohannim et al. 2012a, b; Lourdusamy et al. 2012; Luo et al. 2012;
Mackin et al. 2012; Mattila et al. 2012; Meda et al. 2012a, b; Melville
et al. 2012; Mukherjee et al. 2012a, b;M u r p h ye ta l .2012; Rajagopalan
et al. 2012; Ramanan et al. 2012a; Reitz et al. 2012; Sabuncu et al. 2012;
Samtani et al. 2012;S c h o t t2012; Silver et al. 2012; Silver and Montana
2012; Singh et al. 2012;S o a r e se ta l .2012; Stein et al. 2012;
Swaminathan et al. 2012a, b, c; Thambisetty et al. 2012; Vounou et al.
2012;W a n ge ta l .2012a, b, c;W e i n e re ta l .2012;W o l ze ta l .2012;Y e
et al. 2012;Y ue ta l .2012)
Brain Imaging and Behavior (2014) 8:183–207 185healthy control vs. AD). QT approaches have ~4–10
times more statistical power (Potkin et al. 2009e;
P u r c e l le ta l .2003)( F i g .3), making use of the entire
distribution of trait values, as well as avoiding the often
Fig. 1 Distribution of
publications using the ADNI
APOE and GWAS genotyping
data between 2009 and 2012: Of
the 106 papers, 30 papers used
only APOE data, and 76 papers
used GWAS data
Table 1 Classification of reviewed papers based on genotype, phenotype and method categories with an example
Category # of
papers
Example paper
Genotype APOE alone 30 Soares et al. 2012,A r c h
Neurol
Plasma biomarkers associated with the apolipoprotein E genotype and
Alzheimer disease
Copy number variations
(CNVs)
3 Swaminathan et al.
2012a,P L o SO N E
Analysis of copy number variation in Alzheimer’s disease in a cohort of
clinically characterized and neuropathologically verified individuals
Candidate SNPs 26 Kauwe et al. 2011,P L o S
ONE
Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for
association with cerebrospinal fluid biomarkers for Alzheimer’sd i s e a s e
Candidate genes/pathways 7 Swaminathan et al.
2012c, Brain Imaging
Behav
Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PETin the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort
Genome wide 38 Potkin et al. 2009a,
PLoS ONE
Hippocampal atrophy as a quantitative trait in a genome-wide association
study identifying novel susceptibility genes for Alzheimer’sd i s e a s e
Phenotype Case control 26 Naj et al. 2011,N a t
Genet
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are
associated with late-onset Alzheimer’sd i s e a s e
Structural imaging
(sMRI, dMRI)
55 Shen et al. 2010,
NeuroImage
Whole genome association study of brain-wide imaging phenotypes for
identifying quantitative trait loci in MCI and AD: a study of the ADNI
cohort
Functional imaging
(PET, fMRI)
15 Xu et al. 2010,
Neuroreport
Effects of BDNF Val66Met polymorphism on brain metabolism in
Alzheimer’sd i s e a s e
Fluid (CSF, blood) 24 Kim et al. 2011,
Neurology
Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and
p-tau181p in the ADNI cohort
Neuropsychological
assessments
22 Mukherjee et al. 2012a,
Brain Imaging Behav
Genetic architecture of resilience of executive functioning
Method Univariate analysis 72 Stein et al. 2010a,
NeuroImage
Voxelwise genome-wide association study (vGWAS)
Multivariate analysis 25 Hibar et al. 2011c,
NeuroImage
Voxelwise gene-wide association study (vGeneWAS): multivariate
gene-based association testing in 731 elderly subjects
Meta analysis 12 Stein et al. 2012,
Nat Genet
Identification of common variants associated with human hippocampal
and intracranial volumes
Pathway analysis 8 Ramanan et al. 2012a,
Brain Imaging Behav
Genome-widepathway analysis ofmemoryimpairmentintheAlzheimer’s
Disease Neuroimaging Initiative (ADNI) cohort implicates gene
candidates, canonical pathways, and networks
Interaction and network
analysis
7M e d a e t a l . 2012a,
Neurobiol Aging
Genetic interactions associated with 12-month atrophy in hippocampus
and entorhinal cortex in Alzheimer’s Disease Neuroimaging Initiative
Learningpredictivemodels
or progression profiles
13 Yu et al. 2012,J
Alzheimers Dis
Enriching amnestic mild cognitive impairment populations for clinical
trials: optimal combination of biomarkers to predict conversion to
dementia
Note that a paper could fall into multiple categories
186 Brain Imaging and Behavior (2014) 8:183–207arbitrary or error prone cutoff distinctions, for example,
thresholds that distinguish MCI from AD. This observation
is illustrated by the FRMD6 gene example shown above
(Fig. 2); see also “Strength and limitations of QT analyses”
section for more relevant discussion. In addition, QTanalysis
offers an alternative strategy to discover unanticipated genes
associated with AD or AD risk. One can begin with brain
imaging or other biomarkers characteristic of AD and identify
the genes (or SNPs, or other types of genetic variation) asso-
ciated with that phenotype. Using imaging and biomarkers as
an intermediate phenotype, may have greater sensitivity in
clarifying the functional links related to the AD genes than
diagnostic categories. In the following section, we provide a
systematic review of ADNI genetics findings where imaging,
cognition and biomarkers have been used as quantitative
phenotypes.
Chr 14q22.1 rs11626056
(Potkin 2009)
rs7140150 
(Stein 2010)
rs11626565
(Swedish)
rs17123958
(Li 2008)
rs17586545 
(Reiman 2007)
rs12885443 
(Lambert 2009)
FRMD6
* FERM= 4.1 ezrin radixin moesin
Source SNP Position MAF p-value OR (95%CI)
Stein 2010 rs7140150 52010799 0.4566 4.77 ×10-7 n/a - Imaging QTL
Potkin 2009 rs11626056 52233276 0.3295 1.18 ×10-6 n/a - Imaging QTL
Furney 2011 rs7153703      51919822 0.2130 3.38 x 10-6      n/a - Imaging QTL
Swedish rs11626565 52075152 0.0599 2.45 x 10-5 1.69;1.34-2.13
Reiman 2007  rs17586545 52035018 0.0334 4.18 x 10-5 1.86; 1.36-2.54 
Li 2008  rs17123958 51942124 0.1040 7.59 ×10-5 2.12; 1.38-3.24
Lambert 2009 rs12885443 52075653 0.1769 5.34 x 10-4 1.16; 1.07-1.25
Across the four combined GWAS samples, 
FRMD6 showed the highest non-APOE
signal: p = 2.6 ×10-14). 
Hong et al, Genome-wide and gene-based 
association implicates FRMD6 in Alzheimer 
disease. Hum Mutat. 2012. 33(3):521-9.
rs7153703 
(Furney 2011)
Saykin et al, AAIC 2012
Fig. 2 As reported in (Saykin et al. 2012), FRMD6 (FERM domain-containing protein 6) was detected in 3 imaging genetics studies using the ADNI
data (Potkin et al. 2009a; Stein et al. 2010a; Furney et al. 2011) and validated by case control GWAS (Hong et al. 2012)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1000 2000 3000 4000 5000 6000
P
o
w
e
r
Sample Size
QTs increase power and reduce needed sample sizes
Power  distribution for a QTL trait
QT - p = 10E-8 ca-co [p=10E-8)
Fig. 3 Comparison of sample
sizes to reach a GWAS
significance level of p<10
−8 for
case controls and QTapproaches
for a p<10
−8 (OR=1.5) with
10 % variance explained for the
QT, a MAF of .10 and marker
SNP MAF=.20. (See also Potkin
et al. 2009e)
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as quantitative phenotypes
Structural neuroimaging
Structural neuroimagingisthe mostwidely studiedphenotype
category in ADNI (Table 1). Interesting brain-genome associ-
ations can be identified at multiple levels (Fig. 4): In the
genomic domain, we can examine candidate genes/SNPs,
relevant biological pathways/networks, or the entire genome;
similarly, in the neuroimaging domain, we can study an indi-
vidual region of interest (ROI), interesting brain circuits in-
cluding multiple ROIs, or the whole brain. Figure 4 shows
examples of studies in each category (Chiang et al. 2012;H o
etal.2010;Potkinetal.2009a,c;Reimanetal.2009;Risacher
et al. 2010, 2013; Saykin et al. 2010;S h e ne ta l .2010; Sloan
et al. 2010; Stein et al. 2010a; Swaminathan et al. 2012c).
Below, we first focus on candidate and genome-wide genetic
association studies of targeted brain phenotypes, then whole
brain analysis of targeted SNPs, and finally review whole
genome whole brain analysis.
Note that the findings discussed below included some
“promising” results which did not reach conventionally accept-
ed genome-wide thresholds. In addition, some of the studies
performed various analyses on related phenotypes using the
same dataset. While these studies yielded interesting and prom-
ising results warranting further investigation, readers should be
aware that the issue of determining the proper statistical thresh-
old in these complex quantitative genetics studies is still a
challenging area and a topic of ongoing investigation.
Replication of any of the current results in independent samples
remains of critical importance for confirmation.
Candidate genetic association study of targeted phenotypes
Structural neuroimaging data have been used in many genetic
studies of ADNI data to provide targeted QTs to increase
detection power and improve biological interpretability. The
Fig. 4 Multi-level brain-genome association strategies and examples of
studies in each category (Risacher et al. 2010; Sloan et al. 2010;P o t k i n
et al. 2009a; Saykin et al. 2010;R i s a c h e re ta l .2013; Swaminathan et al.
2012c; Potkin et al. 2009c;H oe ta l .2010;R e i m a ne ta l .2009;C h i a n g
et al. 2012;S h e ne ta l .2010; Stein et al. 2010a). Relevant thumbnails
were reprinted by permissions from (1) Elsevier: [Neurobiology of Ag-
ing], (Risacher et al. 2010), copyright (2010); (2) John Wiley & Sons,
Inc.: [American Journal of Medical Genetics], (Sloan et al. 2010), copy-
right (2010); (3) Elsevier: [Alzheimer's & Dementia], (Saykin et al.
2010), copyright (2010); (4) the terms of the Creative Commons Attri-
bution Non Commercial License: [Frontiers in Aging Neuroscience],
(Risacher et al. 2013), copyright (2013); (5) Macmillan Publishers Ltd:
[Molecular Psychiatry], (Potkin et al. 2009c), copyright (2009); (6) the
terms ofthe CreativeCommons Attribution-Noncommercial-ShareAlike
3.0 Unported License: [Journal of Neuroscience], (Chiang et al. 2012),
copyright (2012); and (7) Elsevier: [Neuroimage], (Shen et al. 2010),
copyright (2010)
188 Brain Imaging and Behavior (2014) 8:183–207relationship of APOE to targeted MRI phenotypes has been
investigated in a few ADNI studies. Wolk and Dickerson
(2010) analyzed mild AD participants with a cerebrospinal
fluid (CSF) molecular profile consistent with AD to show that
carriers of the APOE ε4 allele exhibited greater medial tempo-
ral lobe (MTL) atrophy, whereas non-carriers had greater
frontoparietal atrophy. Andrawis et al. (2012)s h o w e dt h a t
pooled HC, MCI and AD participants with the APOE ε4a l l e l e
hadsignificantlysmallerhippocampalvolumeat1-yearfollow-
up and non-significantly smaller hippocampal volume at base-
line. Jack et al. (2012) showed that the shape of hippocampal
volume trajectory as a function of the Mini-Mental State
Examination (MMSE) score was affected by interactions with
APOE ε4 status. Risacher et al. (2010) showed that annual
percent change rates in MRI-based neurodegeneration markers
are influenced by APOE genotype. Desikan et al. (2012)a n d
Tosun et al. (2010) both performed longitudinal MRI studies to
investigate relations between brain atrophy rate, CSF bio-
markers, and APOE ε4 status.
Several other ADNI studies have also reported the effects of
specific candidate genes on targeted imaging phenotypes.
R i m o le ta l .( 2010) studied sex-dependent association of com-
mon variants of microcephaly genes with brain structure to
identify and confirm two SNPs (rs914592 and rs2297453) in
CDK5RAP2 associated with total cortical surface area in only
m a l e s .B i f f ie ta l .( 2010) reported the association of GWAS-
validated and GWAS-promising novel AD loci with several
imaging phenotypes. Sabuncu et al. (2012) computed a poly-
genic score using candidate AD-related SNPs to examine the
association between a polygenic AD score and cortical thick-
ness in clinically normal participants. Murphy et al. (2012)
showed that in APOE ε4 carriers, the V and A alleles of the
cholesteryl ester transfer protein (CETP) gene were associated
with greater baseline cortical thickness and less 12-month
atrophy in the MTL. Luo et al. (2012) demonstrated that the
genetic variation in the interleukin 3 (IL3)p r o m o t e ri sar e g u -
lator of human brain volume consistent with a novel role of IL3
in regulating brain development.
GWAS study of targeted phenotypes
GWAS analyses have also been performed on targeted MRI
phenotypes in ADNI. Potkin et al. (2009a) performed a QT
analysis on HC and AD participants using hippocampal vol-
ume to identify 21 genes or chromosomal areas with at least
one SNP with P ≤10
−6 including EFNA5, CAND1,a n d
MAGI2 (Potkin et al. 2009a). Stein et al. (2010b) performed a
GWAS to identify 2 SNPs (rs10845840 (GRIN2B)a n d
rs2456930) associated with bilateral temporal lobe volume.
Stein et al. (2011) identified and replicated two genes
(WDR41 and PDE8B), involved in dopamine signaling and
development, associated with right caudate volume. Furney
et al. (2011), combining the ADNI-1 and AddNeuroMed data
sets, performed a GWAS and identified two SNPs (rs1925690
(ZNF292) and rs11129640 (ARPP-21)) associated with ento-
rhinal cortical volume. Gene-wide scoring highlighted
PICALM (phosphatidylinositol-binding clathrin assembly
protein) as the most significant gene associated with entorhinal
cortical thickness. This PICALM finding confirmed an earlier
candidate gene analysis (Saykin et al. 2010) associating
PICALM genotype and baseline mean bilateral entorhinal cor-
tex thickness in ADNI-1. Hibar et al. (2012)p e r f o r m e da
GWAS that identified common SNPs in the FMO gene cluster
associated with differences in lentiform nucleus volume and
replicated rs1795240 in FMO in meta-analysis. Melville et al.
(2012) performed a meta-analysis using 2 different populations
to identify novel GWAS hits associated with hippocampal
volume in the APOE, F5/SELP, LHFP,a n dGCFC2 gene
regions. Bakken et al. (2012) identified and replicated two
SNPs (rs6116869 and rs238295) in GPCPD1, which is highly
expressed in occipital cortex in humans, associated with the
proportional surface area of visual cortex. Two recent large-
scale GWAS analyses (Bis et al. 2012; Stein et al. 2012)
identified and confirmed two SNPs (rs7294919 and
rs17178006) associated with hippocampal volume and one
SNP (rs10784502) associated with intracranial volume.
Saykin et al. (2010) performed a GWAS and identified several
genes (CDH8, SCL6A13, MAD2L2, QPCT,a n dGRB2)i n
addition to APOE and TOMM40 associated with rate of hip-
pocampal volume loss and rate of change in hippocampal gray
matter density over 1 year.
Whole brain analysis of targeted SNPs
A complementary line of research has been the whole brain
analysis of targeted SNPs. In morphometric research, the
traditional approach has been to trace a set of brain structures
on MRI scans—either manually or automatically—and com-
pute their volumes. In parallel, a set of voxel-based methods
has been refined over the years to create statistical maps,
revealing associations between an imaging measure at each
location in the brain, and an external predictor, such as geno-
type. One such method, tensor-based morphometry (TBM),
uses nonlinear deformations to align each participant’sM R I
scan to an average brain template, and the degree of compres-
sion or expansion is used as a measure of regional brain
volume. Using TBM, Ho et al. (2010)s h o w e dt h a tc a r r i e r s
ofanobesity-related SNP inthe FTO genehad lower regional
brain volumes than non-carriers in the frontal and occipital
lobes. ~46 % of Western Europeans carry the obesity-
associated SNP in FTO, and this genetic association with
brain structure offers one plausible biological pathway, to
explain why people with higher body mass index tend to have
smaller volumes for some brain regions. Stein et al. (2010b)
also used TBM to search for common genetic variants asso-
ciated with temporal lobe volume. One such SNP,
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the N-methyl-D-aspartate (NMDA) glutamate receptor NR2B
subunit. This protein, which is involved in learning and mem-
ory,andexcitotoxic cell death,hasage-dependentprevalence in
the synapse and is already a therapeutic target in Alzheimer’s
disease. Risk alleles for lower temporal lobe volume at this
SNP were significantly over-represented in AD and MCI pa-
tients vs. controls (odds ratio=1.3; P=0.039) and were nega-
tively correlated with MMSE score, suggesting lower global
cognitive function. Voxelwise maps of genetic associations
revealed strong temporal lobe effects. Rajagopalan et al.
(2012) also found greater brain atrophy in carriers of the
folate-related gene, MTHFR, and replicated the association in
a young adult cohort. Carriers of a common SNP in this gene
have elevated homocysteine levels. Homocysteine is neurotox-
ic and may itself promote brain atrophy, therefore constituting a
risk for cardiovascular disease that carries additional risk for
AD. The FTO and MTHFR studies targeted SNPs that already
had a known association with a factor that promotes brain
atrophy, suggesting a general “stepping-stone” approach to
focus on brain-relevant SNPs. A number of studies mapped
the effect of APOE genotype on several brain measures in
ADNI, including cortical thickness (Fan et al. 2010) and mem-
ory and MRI measures (Wolk and Dickerson 2010).
Whole genome whole brain analysis
Most genetic analyses of the ADNI dataset—and of brain
image databases in general—have focused on testing the ef-
fects of one or a handful of candidate SNPs. Even so, one can
also search the entire genome for common variants that are
associated with signals in any part of an image. Several pub-
lished papers used the ADNI dataset to perform this kind of
genome-wide, image-wide, search. In a “brute force” ap-
proach, Stein et al. (2010a) proposed “voxelwise GWAS”—
or vGWAS—which explored the relation between 448,293
SNPs in each of 31,622 voxels in the brain across 740 ADNI
participants. No variants survived as associated with regional
brain volumes, but several genes worthy of further exploration
were identified, including CSMD2 and CADPS2.T w os u b s e -
quent papers (Hibar et al. 2011b, c) proposed “vGeneWAS”,
where the SNPs in each gene are first prioritized using a
principal components regression. The top gene in the study
was GAB2, which has been previously associated with late-
onset AD (Reiman et al. 2007), suggesting validity of the
approach. In a combined voxel-wise and ROI approach, Shen
et al. (2010) performed a GWAS, and confirmed that SNPs in
the APOE and TOMM40 genes were strongly associated with
volumetric variation in multiple brain regions. Their genome-
wide, whole brain search also revealed several novel candidate
loci (EPHA4, TP63 and NXPH1) warranting further investi-
gation and replication. The EPHA4 finding was interesting in
that EPHA1, also a member of the ephrin gene family, was
later identified and replicated in two large case control GWAS
(Hollingworth et al. 2011; Naj et al. 2011). The NXPH1
association points to theneurexin and neuroligin gene pathway
whichregulatescell adhesionrelated proteinsthatarereceiving
increasing attention in AD research (Martinez-Mir et al. 2013).
To helpfindsignals indatasetsofsuchvastdimensionality,
sparse regression and machine learning methods have been
adapted by several research groups to handle imaging mea-
sures and identify a compact set of genetic predictors from a
vast set of SNPs (reviewed in Hibar et al. (2011a)). Sparse
reduced-rank regression (sRRR) was proposed and applied to
the ADNI data in Vounou et al. (2012), confirming the key
role of the APOE and TOMM40 genes, and also highlighting
some novel potential associations with AD. Ge et al. (2012)
proposed a new multi-locus method for voxelwise GWAS,
and re-analyzed the TBM dataset from Stein et al. (2010a).
They found a number of genes with statistically significant
associations with regional brain volumes; the most strongly
associated gene was GRIN2B, already implicated by Stein
et al. (2010a), which encodes the N-methyl-D-aspartate
(NMDA) glutamate receptor NR2B subunit and was associ-
ated with parietal and temporal lobe volumes. Meda et al.
(2012b) adapted parallel independent components analysis
(pICA) to whole brain genome-wide analysis, and identified
four primary “genetic components” that were associated with
a single structural network including regions involved
neuropathologically in late-onset AD. In pathway analyses,
each component included several genes known to contribute
to AD risk (e.g., APOE) or pathologic processes contributing
to AD, such as inflammation, diabetes, obesity and cardiovas-
cular disease. Silver et al. (2012) proposed pathways sparse
reduced-rank regression (PsRRR) and applied the method to
voxel-wise maps of brain change, computed using TBM at 6,
12 and 24 month intervals. High ranking genes included a
number previously linked to β-amyloid plaque formation
(PIK3R3, PIK3CG, PRKCA and PRKCB), and several
known AD risk genes—CR1, TOMM40 and APOE.
Functional neuroimaging
A number of ADNI studies investigated how genetic variants
influence functional neuroimaging measures from functional
MRI (fMRI) and PET. The role of APOE ε4 allele, the
strongest known genetic risk factor for late-onset AD, has
been evaluated in many studies. In one fMRI study
(Damoiseaux et al. 2012), the authors found significant de-
creased connectivity in the default mode network in healthy
older participants who carried the APOE ε4a l l e l ec o m p a r e d
to APOE ε3 homozygotes. A significant sex by APOE geno-
type interaction in the precuneus was identified; with a signif-
icant reduction in default mode connectivity observed only in
female ε4 carriers. Jack et al. (2012) evaluated the shape of
five biomarker trajectories including CSF Aβ42 and tau
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11C]Pittsburgh
Compound-B (PiB)-PET, cerebral metabolic rate measured
using [
18F]fluorodeoxyglucose (FDG)-PET, and MRI, as a
function of MMSE (Jack et al. 2012). The authors identified
complex biomarker trajectories, which were affected by age
and APOE ε4 status. A different study in cognitively normal
ADNI participants also showed the association of APOE ε4
status with amyloid burden measured with [
18F]florbetapir
and glucose metabolism measured with FDG-PET (Jagust
and Landau 2012). Interestingly, plasma APOE level was
one of the biomarkers associated with brain amyloid burden
measured by [
11C]PiB-PET in the ADNI cohort (Kiddle et al.
2012).APOE ε4genotypepredictsahigherrateofconversion
of MCI to AD and has been suggested—along with other
markers—for selecting participants for clinical trials (Singh
et al. 2012;Y ue ta l .2012).
Theroleofothergeneticvariantshasalsobeeninvestigated
in a few studies. Xu et al. (2010) investigated the effect of the
Val66Met polymorphism of the BDNF gene on regional ce-
rebral metabolic rate measured by FDG-PET, and found sig-
nificant differences in many brain regions in Met carriers
compared to non-carriers. Searching amyloid-related genes
ina candidate pathway-based analysisofADNI-1 participants
with [
11C]PiB-PET imaging data, an intronic SNP within the
DHCR24 gene was identified, where carriers of the protective
allele showed lower amyloid burden on a whole-brain voxel-
wise level compared to non-carriers (Swaminathan et al.
2012c). Another targeted [
11C]PiB-PET study, combining
the BLSA cohort and ADNI PiB-PET participants, identified
a lower amyloid burden in protective allele carriers compared
to non-carriers of the rs3818361 SNP of the CR1 gene
(Thambisetty et al. 2012). A SNP by APOE interaction was
also observed: APOE ε4 carriers showed a significantly
higher amyloid burden compared to APOE ε4 non-carriers,
in non-carriers of the CR1 allele.
Fluid biomarkers
To date, explorations of ADNI fluid biomarkers have helped to
identify novel candidate loci for CSF biomarker levels, to
characterize biomarker effects of established and candidate
ADriskmarkers,andtoanalyzecombinationsoffluid,imaging
and genetic data in order to predict AD status and AD
conversion.
Attempts to identify novel genetic variants have used an
endophenotype-based approach, first working to understand
how variants influence cerebrospinal fluid levels, then testing
those variants as candidates to modify disease risk or other
aspects of disease. As demonstrated by Schott (2012)u s i n g
ADNIdata,thisapproachmayreduceheterogeneityinclinical
diagnosis, increasing power to detect genetic associations. In
addition, this approach leverages the strengths of quantitative
traits and provides a clear biological mechanism for disease
modifying action of the identified variants. Genome-wide
association studies of cerebrospinal fluid levels of Aβ42 and
tau/p-tau have been conducted in the ADNI dataset. Han et al.
(2010) and Kim et al. (2011) completed two first GWAS
analyses of CSF biomarkers, and these studies confirmed the
known associations between APOE ε2/ε3/ε4 genotype and
these AD biomarkers and reported suggestive associations with
other genetic variants. Use of the ADNI data in combination
with similar data from other groups has led to the identification
of variation in PPP3R1, which is associated with cerebrospinal
fluid p-tau levels and rate of decline in AD patients (Cruchaga
et al. 2010). These findings were recently confirmed in another
dataset (Peterson et al. 2013) and represent a clear example of
the successful use of ADNI data in executing an
endophenotype-based approach to discover novel disease mod-
ifying variants. More recently Cruchaga et al. (2013)p u b -
lished a genome-wide association study of cerebrospinal
fluid tau levels using more than 1,200 samples, includ-
ing ADNI data. This study identified three new genome-
wide significant loci for cerebrospinal fluid tau levels
including rs9877502, which is located at 3q28 between
GEMC1 and OSTN, and also shows association with
AD risk, tangle counts in AD patients, and cognitive
decline. While Aβ42 and tau levels have been the focus
of these studies, ADNI data for other proteins found in
blood and/or cerebrospinal fluid have also yielded inter-
esting results. Lourdusamy et al. (2012)u s e dA D N Id a t at o
confirm associations between plasma levels of several disease
related proteins and cis-located genetic variants. A genome-
wide association study of cerebrospinal fluid APOE levels
showed association to the APOE ε4 allele and several other
suggestive associations (Cruchaga et al. 2012).
There has been frequent use of fluid biomarkers to further
characterize the biological effects of reported AD risk markers
(Alexopoulos et al. 2011;C r u c h a g ae ta l .2011, 2013;K a u w e
et al. 2010b, 2011;S o a r e se ta l .2012;V e m u r ie ta l .2010). In
addition to the well-established associations between the
APOE ε4 allele and cerebrospinal fluid Aβ and tau levels,
associations between variants in SORL1 and CSF Aβ levels
(Alexopoulos et al. 2011) and between variants in BIN1,
CD2AP, PICALM and CR1 and cerebrospinal fluid tau levels
(Cruchaga et al. 2013) were also reported. Soares et al. (2012)
examined the association of APOE ε2, ε3, ε4 genotype with
multiple analytes and provided evidence for association with
cortisol, interleukin 13, apolipoprotein B, and gamma interfer-
on levels (Soares et al. 2012).
Finally, fluid biomarker data combined with genetic and
imaging data have been used to classify case controls status
and to predict biomarker trajectory (Hu et al. 2012;J a c ke ta l .
2012;K i d d l ee ta l .2012; Tosun et al. 2010;W o l ze ta l .2012;
Yu et al. 2012). Research by Jack et al. (2012) shows the
complexity of the relationships between biomarkers and AD,
aswellastheimportanceofageandAPOE ε4ge no ty peinth e
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results of these studies suggest combined evaluation of these
factors can provide information to improve diagnosis (Hu
et al. 2012; Kiddle et al. 2012; Tosun et al. 2010) and predic-
tion of conversion from non-demented to Alzheimer’sd i s e a s e
status (Wolz et al. 2012;Y ue ta l .2012).
In sum, fluid biomarker data in ADNI has been leveraged
using several strategies. These data have helped to discover
novel genetic variants that modulate AD, to characterize ef-
fects of AD risk variants, and have improved diagnostic and
prognostic evaluations.
Cognitive performance, clinical measures, and other QTs
Neuropsychological performance scores and other measures,
including age at onset of AD symptoms and neuropsychiatric
inventory questionnaire variables, have been used in several
ADNI studies as quantitative phenotypes or independent pre-
dictors to investigate the roles of genetic variants. Many
studies have focused on the role of APOE genotype. APOE
ε4 alleles were more frequent in the memory deficit group
(amnestic phenotype) than the dysexecutive function group
(dysexecutive phenotype)inmildADpatients(Dickersonand
Wolk 2011)a n dε4-carriers displayed greater impairment of
memory retention compared to ε4-noncarriers in AD patients.
ε4-noncarriers showed more impairment in working memory,
executive function, and lexical access (Wolk and Dickerson
2010). However, no significant relationship between APOE
alleles and dysexecutive and amnestic phenotypes was found
in another study using a different phenotypic approach
(Mukherjee et al. 2012b). While these studies focused on
APOE ε4-carriers compared to ε4-noncarriers, another study
examined the role of the protective APOE ε2a l l e l e( B o n n e r -
Jackson et al. 2012). The ε2 allele was associated with slower
changes in daily functioning over time and better neuropsy-
chological performance across a number of measures, dem-
onstratingthe expectedprotectiveeffectofAPOE ε2 allele. In
addition,therelationshipbetweensubsyndromalsymptomsof
depression (SSD) in MCI patients and APOE ε4 allele carrier
status was investigated with a higher frequency of ε4 allele
carriers found in participants with SSD (Mackin et al. 2012).
While many studies investigated a targeted set of SNPs,
other studies have performed GWAS of cognitive decline of
patients with MCI (Hu et al. 2011b), of age-at-onset of AD
(Kamboh et al. 2011), of global cognitive decline in several
studies with mixed diagnoses (De Jager et al. 2012), of exec-
utive functioning resilience (Mukherjee et al. 2012a), and of a
composite measure of memory performance (Ramanan et al.
2012a). ADNI data were used as a discovery or replication
sample in these studies. Sherva et al. (2013)p e r f o r m e da n
unbiased GWAS on rate of cognitive decline in patients with
AD that included ADNI participants. These studies identified
the association of SNPs from AD-candidate genes (PICALM
and CLU) and novel genes (UBR5, DCHS2, RNASE13,
FLJ10357, SORL1) and enriched pathways in GWAS data.
Two studies integrated multi-modal data including imag-
ing, genetics and/or cognitive data to improve the classifica-
tion accuracy (Yu et al. 2012), as well as the prediction
accuracy, of neuropsychological performance (Wang et al.
2012b). One study identified a significant association of one
coding variant in CR1 gene with episodic memory decline
(Keenan et al. 2012). SNPs previously associated with AD,
white matter hyperintensity (WMH), and MRI-identified in-
farcts were also investigated (Mukherjee et al. 2012b). This
study found 58 AD-related and 25 WMH- or infarct-related
SNPs with odd ratios >1.5 or <0.67 in the amnestic subgroup
ofADpatientsincontrasttothedysexecutivesubgroup.Other
targeted studies examined the relationship between SNPs in
COMT gene and the presence of apathy (David et al. 2011)
and between circadian related SNPs and sleep–wake state
(Yesavageetal.2011).However,thesestudiesdidnotobserve
any significant associations.
Analytical strategies
Univariate analysis and multiple testing issues
Univariate analysis is widely used in genetic association stud-
ies. Among 106 ADNI papers reviewed here, 72 performed
univariate analyses (Table 1). Typical methods used in uni-
variate analysis include Pearson’s chi-squared test as the stan-
dard case control allelic test, or linear regression of the phe-
notype on the allele dosage for quantitative trait analysis
(Purcell et al. 2007). As appropriate, covariates are often
included in these analyses to remove effects of confounding
factors such as APOE status (e.g., Kim et al. (2011)), and
different genetic models (e.g., additive, dominant, or reces-
sive) are sometimes considered (e.g., Cruchaga et al. (2010)).
The concern of protecting against type 1 false positive
errorsiscrucialhere.Useofunbiasedgenediscoverymethods
raises important issues related to false positive findings as the
number of associations tested can exceed one million.
Classical statistical analytical techniques were not designed
for situations where the number of variables exceeds the
number of participants by many orders of magnitude. The
classical approach treats each association considered between
a SNP and the phenotype as a “repeated” test, and argues that
one should correct for the number of tests performed (e.g.,
with Bonferroni’s method, see critique by Gombar et al.
(2012)). The widely-used Bonferroni method is not ideal for
this application, as it assumes that all the factors, the SNPs in
this case, are statistically independent of each other. However,
this is not accurate for the genome or typically the case in
imaginggeneticsstudies where mostSNPs are correlatedwith
other SNPs (via linkage disequilibrium (LD) dependencies)
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10
−8 and Bonferroni corrections have been applied and
questioned as either too conservative or too liberal. One
alternative is permutation (arbitrarily reassigning diagnostic
and/or genotypes to estimate a null distribution of the test
statistic (Collingridge 2013)) analysis (e.g., used in Stein
et al. (2010b)). This has been used to identify adjusted thresh-
olds for single SNPs, avoiding the need to meet assumptions
ofnormalitybutishighlycomputationallydemandingandcan
be slow even running on advanced supercomputers. False
discovery rate (FDR) (Benjamini and Hochberg 1995)( e . g . ,
used in Biffi et al. (2010)) is an alternative to the family wise
errorrate(FWER)(HochbergandTamhane1987)andmaybe
more appropriate to balance the complementary risks of false
positives and false negatives. False negatives can be poten-
tially more harmful than false positives, since they may be
discarded forever, while a false positive can always be
disproved or “falsified” later, albeit at some cost.
Examples of ADNI studies using a univariate analysis
strategy include those evaluating: (1) candidate SNP/gene
analyses on disease status (Lakatos et al. 2010), imaging
measures (Biffi et al. 2010), fluid biomarkers (Kauwe et al.
2011), and cognitive scores (Dickerson and Wolk 2011), and
(2) GWAS analyses of disease status (Potkin et al. 2009a),
imaging measures (Shen et al. 2010), fluid biomarkers (Kim
et al. 2011), and cognitive scores (Mukherjee et al. 2012a).
The “voxelwise GWAS” proposed in Stein et al. (2010a)i sa n
extreme case of massive univariate analysis. It examined the
association between each possible SNP and voxel pair, and
retained the most highly associated genetic variant at each
voxel, to reduce the computational burden associated with the
data. After applying an inverse beta transform to define an
appropriate multiple comparisons correction, this study iden-
tified no significant SNP-voxel associations but several prom-
ising variants warranting further investigation.
Most genetic analyses of the ADNI dataset—and of brain
image databases in general—have focused on the univariate
strategy. This approach can quickly identify important single-
SNP-single-trait associations, which are easy to interpret.
However, this approach treats SNPs and traits as independent
units, and overlooks relationships in which multiple SNPs
jointly affect a single trait or multiple traits as well as pleiot-
ropy, where one genetic locus influences multiple phenotypic
traits. This may potentially lead to overly conservative statis-
tical thresholds. To address these issues, multivariate analysis
has also been employed in the ADNI genetics studies, and is
discussed in the following section.
Multivariate analysis
Tofurtherboostthedetectionpower,someADNIstudieshave
proposed or employed polygenic or multi-locus approaches,
modeling the combined effect of multiple SNPs across the
genome (Hibar et al. 2011a). For example, Biffi et al. (2010)
calculated a cumulative score to represent the combined effect
of a few non-APOE candidate SNPs, and identified its signif-
icant association with neuroimaging and clinical outcomes.
Kohannim et al. (2011) and Kohannim et al. (2012a)u s e d
novel regression models to boost power to detect genetic
associationswithimagingphenotypes. Inparticular,theyused
LASSO regression to evaluate gene effects in a GWAS of the
temporal lobe volume and discovered 22 genes that passed
genome-wide significance. The effectofthe MACROD2 gene
was successfully replicated in an independent cohort
(Kohannim et al. 2012b).
Following the univariate “voxelwise GWAS” by Stein et al.
(2010a), two subsequent papers (Hibar et al. 2011b,c) proposed
“vGeneWAS”, a multivariate version of voxelwise GWAS. In
“vGeneWAS”, the SNPs in each gene are first encoded using a
principal components regression, and then combined effects of
these SNPsaretestedagainst imagevoxelsinthebrain.Another
novel multivariate version of voxelwise GWAS was proposed
by Ge et al. (2012), where they used a multi-locus model based
on least squares kernel machines to associate the joint effect of
several SNPs with neuroimaging traits.
To help find signals in datasets of vast dimension in both
imaging and genomic domains, sparse regression methods
have also been adapted by several research groups to handle
imaging measures and identify a compact set of genetic pre-
dictors from a vast set of genotypes SNPs (reviewed in Hibar
et al. (2011a)). Vounou et al. (2010) proposed a sparse
reduced-rank regression (sRRR) method to detect whole
genome-whole image associations, and detected simulated
genetic effects introduced into a number of ROIs. Relative
to standard univariate modeling, they generally obtained
higher detection sensitivities with sRRR, and rapid gains in
sensitivityasthesamplesizeincreased.Alaterreport,Vounou
etal.(2012)usedlineardiscriminantanalysistofirstfindbrain
voxels in structural brain images that helped to classify indi-
viduals as AD or normal elderly. They then used this multi-
variate biomarker as a phenotype and performed sRRR anal-
ysis against the entire genome, which yielded promising re-
sults. A further refinement of sRRR was proposed by Silver
and Montana (2012). Their method, known as pathways
sparse reduced-rank regression (PsRRR), uses group lasso-
penalized regression to jointly model the effects of genome-
wide SNPs, but also groups them into functional pathways
using prior knowledge of gene–gene interactions. Wang et al.
(2012a) proposed a sparse multitask regression model that
took into account the group structure within the predictors
and demonstrated improved performance on predicting can-
didate AD MRI phenotypes using SNPs from 37 top AD risk
genes. A relevant study by the same group proposed a novel
task-correlated longitudinal sparse regression model and
showed its promise for relating longitudinal MRI phenotypes
to AD risk genes (Wang et al. 2012c).
Brain Imaging and Behavior (2014) 8:183–207 193Bi-multivariate correlation models have also been applied in
ADNI genetics studies. Meda et al. (2012b) adapted parallel
independent components analysis (pICA) to whole brain
genome-wide analysis. A popular method for discerning func-
tional networks in resting-state functional MRI scans, pICA
identified several genetic components that were associated with
an AD-relevant structural brain network. Wan et al. (2011)u s e d
elastic net (EN) and sparse canonical correlation analysis
(sCCA) to examine SNP associations with hippocampal shape.
Sparse regression and correlation methods outperformed stan-
dard multiple regression, suggesting the power and efficiency
of sparse learning methods in imaging genetics.
A few other multivariate methods have also been used in
ADNI genetics studies: (1) Reitz et al. (2012) performed
haplotypeanalysisforrelatingFTO SNPstodiagnosticstatus,
(2) Sabuncu et al. (2012) calculated a polygenic ADscore and
studied its association with cortical thickness, and (3)
Swaminathan et al. (2012c) employed a candidate gene path-
way set-based PLINK analysis to identify genes associated
with amyloid imaging measures. In addition, many conven-
tional and novel multivariate machine learning methods (in-
cluding regression and/or classification) have been applied to
predict APOE status (Soares et al. 2012), cognitive status
(Wang et al. 2012b;W o l ze ta l .2012), diagnostic status
(Mattila et al. 2012;W a n ge ta l .2012b;W o l ze ta l .2012),
and/or disease conversion (Singh et al. 2012;Y ee ta l .2012;
Yu et al. 2012) from ADNI multimodal genetic and pheno-
typic measures.
Itisobviousthatthesemultivariatemethodsprovideboosted
power to identify complex multi-SNP-multi-trait relationships
that univariate approaches are unable to reveal. They are espe-
cially suitable for studying disorders with complex genetic and
phenotypicstructures,suchasAD.Ontheotherhand,giventhe
complexity of the identified multi-SNP-multi-trait patterns, it
remains a challenge to convert this information into biological-
ly meaningful interpretation.
Meta-analysis
Meta-analysis of GWAS results has become a popular strategy
for gene discovery and validation (Evangelou and Ioannidis
2013). Meta-analysis provides a means to quantitatively syn-
thesize GWAS findings from multiple independent studies and
has the potential to increase statistical power and reduce false
positives. The AlzGene database (http://www.alzgene.org/)
provides a collection of meta-analysis results of genetic asso-
ciation studies usingAD riskas the primary phenotype ineither
population-basedorfamily-basedcohorts(Bertrametal.2007).
A number of case control studies combined ADNI results with
results from multiple other cohorts and performed meta-
analytic analyses, including candidate gene studies (Antunez
et al. 2011b; Jun et al. 2010; Reitz et al. 2012), GWAS analyses
(Antunez et al. 2011a; Hollingworth et al. 2011; Kamboh
et al. 2012; Naj et al. 2011), as well as a copy number
variation (CNV) study (Swaminathan et al. 2012a).
Meta-analysis has also been performed on several quantita-
tive trait studies using ADNI multimodal phenotype data. The
largest study was done by the Enhancing Neuro Imaging
Genetics through Meta-Analysis (ENIGMA) consortium
(http://enigma.loni.ucla.edu/)( S t e i ne ta l .2012). This study
identified common variants associated with human hippocam-
pal and intracranial volumes. It discovered an intergenic variant
rs7294919 associated with hippocampal volume (12q24.22;
N=21,151; P=6.70×10
−16), an HMGA2 locus rs10784502
associated with intracranial volume (12q14.3; N=15,782; P=
1.12×10
−12), and a suggestive association with total brain vol-
umeatrs10494373withinDDR2 (1q23.3;N=6,500; P=5.81×
10
−7). Other meta-analysis studies where ADNI was included
have been performed on findings from GWAS association
studies of cognitive measures (Hu et al. 2011a), visual cortical
surface area (Bakken et al. 2012), lentiform nucleus volume
(Hibar et al. 2012), and hippocampal volume, total cranial
volume, and white matter hyper-intensities (Melville et al.
2012), as well as on candidate gene (IL3) findings on brain
volume, gray matter volume, and white matter volume (Luo
et al. 2012).
Meta-analysis offers a quick and convenient approach to
generalize results to a larger population, especially when a
combined analysis is impractical among multiple sites (e.g.,
differences in imaging protocols, genotyping platforms, and/or
data sharing policies). As more data is included, the statistical
power will typically be increased to detect an effect. However,
meta-analysis should be carefully conducted. If the study diver-
sity is ignored (e.g., variability of participants, quality of data,
potential for underlying biases), the increased statistical power
might be lost and the meta-analysis results could be misleading.
Pathway analysis
Pathway analysis (or gene set enrichment analysis) tests for
collective effects among multiple variants within the same
biological pathway and represents an emerging strategy that
may better connect genetic associations to biological interpre-
tations (Cantor et al. 2010; Hirschhorn 2009; Ramanan et al.
2012b; Wang et al. 2010). A typical pathway enrichment
analysis includes the following steps: (1) select one or more
pathways to be tested in a hypothesis driven approach (e.g.,
(Sloan et al. 2010)) or test all pathways in a hypothesis-free,
discovery-oriented approach; (2) select one or more appropri-
ate knowledge bases to delineate the genes in the pathway(s)
or to score gene relatedness; (3) assign SNPs to a gene or
genetic region; (4) use a pathwayscoringsystemtoscore each
pathway or to identify the most implicated gene in a region;
(5) use a statistical framework (e.g., permutation as
implemented in GENGEN or bootstrapping as implemented
inALIGATOR(Holmansetal.2009),amongothers)totestfor
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extant strategies for implementing these steps can impact the
overall pathway enrichment outcome. Some algorithms (such
as GENGEN) require individual genotype and phenotype data,
while others only require summary association statistics. For
example,textminingtoolssuchasGRAIL(Raychaudhurietal.
2009)and Chilibot(Chen and Sharp 2004)typically query alist
of genes or SNPs to identify functional relationships based on
published literature. Other quantitative methods such as
GENGEN (Wang et al. 2009), GSA-SNP (Nam et al. 2010),
the SNP ratio test (O’Dushlaine et al. 2009), and over-
representation algorithms in the Ingenuity (http://www.
ingenuity.com/) and MetaCore (http://portal.genego.com/)
commercial software packages typically use rankings or
other summary statistics from genetic studies to test
for trends of association across multiple genes.
Existing pathway analysis methods have a variety of
strengths and limitations and can be more or less conservative
in relation to statistical confounders such as LD and pathway/
gene size (Ramanan et al. 2012b). Nevertheless, pathway-
based approaches can have increased power to discover func-
tionalrelationshipsthatareconcealedatthelevelofindividual
SNPs or genes (Ramanan et al. 2012b;W a n ge ta l .2010). In
addition, pathways occupiedbyrobustly-associated genes can
highlight additional genes with more modest effects on sus-
ceptibility but which may provide better targets for biomarker
and drug development (Penrod et al. 2011). Finally, pathways
may be more likely to bridge differences in genotyping plat-
forms, phenotype processing, and the distribution of common
and rare variants across populations, which can impair repli-
cation at the SNP or gene level.
Several pathway-based strategies have been successfully
applied to ADNI data and reinforce these potential benefits.
For example, a pathway analysis of CSFAPOE levels identi-
fied lipid metabolism processes as enriched with genetic as-
sociation even after removing APOE SNPs from the analysis,
furthersupportingthehypothesisthatlipid-relatedgenesother
than APOE contribute to AD neuropathology (Cruchaga et al.
2012). Similarly, despite finding no genome-wide significant
associations at the SNP level after controlling for APOE ε4
allele status, a pathway analysis of episodic memory impair-
ment found enrichment of association in numerous pathways,
including those related to neurotransmission, calcium and
cAMP response element binding protein (CREB) signaling,
long-term potentiation, cell adhesion, and inflammation
(Ramanan et al. 2012a). Further, Hu et al. (2011a)u s e d
GENGEN to demonstrate replication of association for the
Gleevec signaling pathway in three independent case control
data analyses including ADNI. These results provide striking
complements tothose obtainedvia standardmethods focusing
on individual genetic variants.
Pathways can also be used to focus analyses of smaller
samples with rich endophenotypes such as amyloid imaging
(Swaminathan et al. 2012c), to find common threads across
multimodal phenotype analyses (Meda et al. 2012b), or to
constrain the search space for computationally demanding
approaches such as gene–gene interaction analyses (Meda
et al. 2012a). The ability to prioritize pathways of interest
may be particularly important to maximize the utility of
next-generation sequencing (NGS) data, given its high gran-
ularity and facility for studying common, rare, and structural
genetic variation that is more difficult to assess using GWAS
alone.
Interaction and network analysis
Most reviewed studies examined the main effect of genetic
predictors, but some studies investigated whether SNP-by-
SNP interaction or SNP-by-phenotype interaction can affect
various ADNI phenotypes. These interaction analyses may
explain part of the “missing heritability” in AD. Examples of
ADNISNP-by-phenotypeinteractionresultsincludetheeffect
of multiple SNP-by-diagnosis interactions (e.g., MAGI2,
EFNA5) on hippocampal volume (Potkin et al. 2009a), asso-
ciation between the interaction of a CR1 coding variant and
APOE ε4 status and episodic memory decline (Keenan et al.
2012), an interaction between CR1 and APOE which was
associated with brain amyloid phenotype (Thambisetty et al.
2012),anassociationbetweenaninteractionamong APOE ε4
vs CSF p-tau/Aβ and entorhinal cortex atrophy rate (Desikan
et al. 2012), and biomarker trajectory shapes as functions of
MMSE that were affected by interactions with age and APOE
status (Jack et al. 2012). In addition, two studies
performed SNP-by-SNP interaction analyses. Kauwe
et al. (2010a) demonstrated that an epistatic interaction
between TF and HFE variants was significantly associ-
ated with AD risk. Meda et al. (2012a) studied gene–
gene interactions within biological pathways associated
with 12-month atrophy rate in regional brain volume
from the hippocampus and entorhinal cortex, and iden-
tified 109 SNP–SNP interactions for right hippocampal
atrophy and 125 for right entorhinal cortex atrophy.
Enrichment analysis indicated significant SNP–SNP in-
teractions were over-represented in the calcium signaling
and axon guidance pathways for both hippocampal and
entorhinal cortex atrophy, as well as in the ErbB sig-
naling pathway for hippocampal atrophy. This study
also constructed gene–gene interaction networks for en-
torhinal and hippocampal atrophy, respectively.
Interactionanalyseshavethepotentialtoexplainpartofthe
“missing heritability” in AD. However, given the exponential
nature of the search space, identifying high order interactions
is not only computationally intensive but also statistically
challenging. Developing effective strategies to address these
challenges is still an active research topic in bioinformatics
(Pan et al. 2013).
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Major findings and implicated biological pathways
Shown in Supplemental Table 1 is a summary of major find-
ings using ADNI genetics data, compiled according to the
following criteria: (1) Only SNP-based and gene-based find-
ings are included; (2) Pathway analysis results are not includ-
ed; (3) Gene–gene interactionresults (e.g.,Meda et al.(2012a)
and Kauwe et al. (2010a)) are not included; (4) If SNPs or
genes are mentioned in the abstract, we include results only
from these SNPs or genes (to prevent the table from growing
too large); (5) If no SNP or gene is mentioned in the abstract,
we include findingssatisfyingoneofthefollowingconditions:
uncorrected p ≤0.00001 for GWAS studies, uncorrected
p≤0.01 for candidate SNP/gene studies, or corrected p≤0.05
if no uncorrected p-values are available. Criterion 5 was deter-
mined with the following considerations: (a) most studies re-
porteduncorrectedpvalues;(b)somestudiesreportedcorrected
p values with a variety of different correction schemes, making
it hard for comparison; (c) p value thresholds were determined
not based on statistical significance but to include a reasonable
number of top hits from each paper. Of note, the FRMD6 gene
(Fig. 2) was not included in this table. Although it was identi-
fied in each of multiple studies (Furney et al. 2011; Potkin et al.
2009a; Stein et al. 2010a) with uncorrected p≤0.00001, the
abstracts of these studies highlighted other more significant
findings. The gene names in this table are either from the
corresponding papers or extracted from SCAN (http://www.
scandb.org/, a SNP and CNV Annotation Database) by
querying the corresponding SNPs.
Several points regarding the sample size (N) of these stud-
ies are noteworthy. Almost all these studies analyzed the
ADNI Phase 1 (ADNI-1) cohort, where the GWAS data were
available on 818 ADNI-1 subjects, including 229 HC, 396
MCIand193ADparticipantsatthebaseline.InSupplemental
Table 1, we specified which ADNI groups (HC, MCI, and/or
AD) were included in the analyses; see the “cohort” column.
After standard quality control (QC) and population stratifica-
tion procedures for GWAS data, the total QC’ed sample
typically included approximately 750 or less Caucasian par-
ticipants. For some QT analyses, the phenotype data were
available only on a subset of participants, e.g., half of
ADNI-1 participants with CSF biomarker data, half with
FDG-PET, and ~100 with PiB-PET. Therefore, in some cases
the QT analysis with these phenotypes had a reduced sample
size.Some studies treatedMCI convertersasADpatients,and
thus the AD sample size could be increased and MCI de-
creased when the longitudinal diagnosis information was
used. Some studies coupled the ADNI cohort with other
cohorts for combined analysis or meta-analysis, which could
resultina larger N.We refer readers tothe sourcepublications
for the actual N.
The top 10 AD genes (APOE, BIN1, CLU, ABCA7, CR1,
PICALM, MS4A6A, CD33, MS4A4E, CD2AP) based on
large case control GWAS (Hollingworth et al. 2011; Naj
et al. 2011) listed in the AlzGene database (http://www.
alzgene.org/) were all discovered or replicated in these
ADNI genetics studies and are included in Supplemental
Table 1. In particular, several of these top hits were
associated with ADNI quantitative phenotypes. For example,
the APOE ε4 allele was associated with CSF Aβ42 and tau/
Aβ42 (Kim et al. 2011), annual percent change of hippocam-
pal volume (Saykin et al. 2010), total cerebral volume and
hippocampal volume (Melville et al. 2012), entorhinal cortex
thickness, hippocampal volume and temporal pole cortex
thickness (Biffi et al. 2010), and multiple MRI measures
(Shenetal.2010).BIN1 was associatedwithentorhinalcortex
thickness (Biffi et al. 2010). CLU was associated with CSF
Aβ42andp-tau(Kauweetal.2011).CR1 wasassociatedwith
brain amyloid burden (Thambisetty et al. 2012) and episodic
memory decline in healthy and cognitively impaired elders
(Keenan et al. 2012). Several PICALM variants were associ-
atedwithentorhinalcortexthickness(Biffietal.2010; Furney
et al. 2011; Saykin et al. 2010) and CSF p-tau (Kauwe et al.
2011).
Inadditiontothese topADgenes,several othergenes were
associated with different quantitative traits and discovered in
multiple ADNI studies. For example, an APOC1 variant was
associated with age-at-onset (Kamboh et al. 2011) and with
rate of cognitive decline in elders with mixed phenotypes (De
Jager et al. 2012) , while variants in SORL1 were associated
with rate of decline in patients with AD. Different FTO
variants were found to be associated with MRI phenotypes
(Ho et al. 2010) and with disease status (Reitz et al. 2012).
GRIN2B was associated with MRI phenotypes in multiple
studies using different methods (Ge et al. 2012;K o h a n n i m
et al. 2012a; Stein et al. 2010b). MAGI2 was associated with
hippocampal volume (Potkin et al. 2009a) and temporal lobe
volume (Kohannim et al. 2012a). TOMM40 was found to be
associated with disease status (Naj et al. 2010; Potkin et al.
2009a), with MRI traits (Saykin et al. 2010;S h e ne ta l .2010),
and with CSF biomarkers (Cruchaga et al. 2012; Kim et al.
2011; Schott 2012). Overall, 14 genes (APOC1, APOE,
BIN1, CD2AP, CLU, CR1, EPHA1, FTO, GRIN2B,
MAGI2,MS4A4A,PICALM,TOMM40) havebeenreplicated
by at least two groups and in some cases (APOE, PICALM,
TOMM40) by up to seven independent analyses. TOMM40
and APOC1 signals are in strong LD with APOE and are
therefore often considered to be indicating the APOE locus
(Junetal.2012),thoughthe topic ofmultiplesignalsfromthis
key region remains under investigation.
To better understand the broader functional implications of
these findings, we performed pathway enrichment analysis
using the MetaCore software package (http://portal.genego.
com/). We mapped all the 101 unique hit genes from ADNI
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Metacore objects. Top enrichment results are shown in
Table 2. Significantly enriched results (FDR p≤0.05, see also
Supplemental Fig. 1)b ycanonical pathway maps, which
represent a set of signaling and metabolic maps covering
human biology in a comprehensive way, include “cell
adhesion, ephrin signaling”, “neurophysiological process,
nNOS signaling in neuronal synapses”, “neurophysiological
process, NMDA-dependent postsynaptic long-term potentia-
tion in CA1 hippocampal neurons”, “immune response, alter-
native complement pathway”,a n d“development, neurotrophin
family signaling”. Significantly enriched results (FDR p≤0.05)
by cellular and molecular process networks include “develop-
ment, neurogenesis, axonal guidance”, “cell adhesion, synaptic
contact”, “development, regulation of angiogenesis”, “cell ad-
hesion, attractive and repulsive receptors”,a n d“development,
neurogenesis, synaptogenesis”. The top 5 enriched results
(FDR p≤1.4×10
−24)b ydiseases include “Alzheimer’sd i s -
ease”, “tauopathies”, “mental disorders”, “late onset
Alzheimer’sd i s e a s e ”,a n d“psychiatry and psychology”.
Some of these pathways, including those related to cell adhe-
sion, complement activation and immune responses, and
neurotrophic signaling reinforce extant leading hypotheses
about the pathogenesis of AD (Crehan et al. 2012; Liu et al.
2012; Rubio-Perez and Morillas-Ruiz 2012; Wyss-Coray and
Rogers2012).Meanwhile,otherpathwayssuchasthoserelated
to nitric oxide signaling and angiogenesis may represent
underexplored or novel targets for future genetic, molecular,
and pharmacologic studies.
As a complementary approach, we also performed a net-
work analysis using Chilibot (Chen and Sharp 2004)o n5 1
genes discovered from ADNI structural MRI genetic studies.
Chilibot (http://www.chilibot.net/) searches PubMed abstracts
and constructs content–rich relationship networks among
biological concepts, genes, proteins, or drugs. No
relationship was reported for five genes: BICD1, CAND1,
GPCPD1, MAD2L2,a n dPRUNE2. We further filtered the
graph by displaying only interactive relationships (i.e.,
excluding non-interactive relationship and abstract co-
occurrenceonly).Figure5 shows the resulting graph,contain-
ing 46 (51−5) query terms, which provides an aerial view of
thegenesassociatedwithADNIstructuralMRIphenotypes.It
also shows the stimulative and/or inhibitory relationships
among these genes, as well as how many PubMed abstracts
support each of these relationships. The findings from
MetaCore and Chilibot synthesize key disease-related mech-
anisms highlightedbythe wealthofADNI genetic studies and
provide novel targets for further analyses.
Molecular validation and other follow-ups
Genetic studies provide potential insights into novel disease
mechanisms. The Aβ hypothesis was first identified from
pathological evidence but is further supported by genetic
evidence in early-onset familial Alzheimer’sd i s e a s e .I nl a t e -
onset Alzheimer disease, approximately 10 loci have been
robustly associated with AD susceptibility and other interme-
diateendpoints(reviewedabove).Molecularcharacterizations
of these findings have started to emerge, beyond APOE that
was discovered two decades ago. Recent studies suggested
that the PICALM gene may be involved in Aβ transportation
across the blood–brain barrier and Aβ internalization (Baig
et al. 2010;X i a oe ta l .2012). Another variant in CR1 has
drawn considerable attention since potential functional varia-
tions of the gene have been proposed either through structural
variation (Brouwers et al. 2012) or a coding variant that may
be associated with episodic memory decline (Keenan et al.
2012). Molecular characterization of this gene is challenging
as a single gene in the mouse encodes CR1 and CR2 while
two separate genes are present in humans (Jacobson and Weis
2008).
Each of the additional genetic loci from GWAS studies
defines a region rather than pin-points a causal gene/variant,
which can limit the scope of the molecular characterization.
Initial regional sequencing and eQTL studies for CLU,
PICALM, CR1, BIN1, MS4A6A/MS4A4E, CD33, CD2AP,
ABCA7, and EPHA1 have not successfully identified com-
mon variants explaining the regional expressions of the genes
in the brain or additional coding variants responsible for the
observed association signal (Holton et al. 2013). Future stud-
ies will likely require larger sample sizes and more compre-
hensive characterizations of the RNA species in the brain
regions (e.g., RNA sequencing). Other novel promising tech-
nologies to follow up genetic loci include induced pluripotent
stem cell models that carry the genetic background from the
patient.
Discussion and future directions
Summary of analytical strategies and biological findings
We have provided a systematic review of 106 papers pub-
lished between 2009 and 2012, which analyzed ADNI APOE
and GWAS data (Fig. 1, Table 1). We presented an overview
of genetic findings from case control studies, as well as
association analyses of multi-modal quantitative phenotypes
including structural neuroimaging, functional neuroimaging,
fluid biomarkers, and cognitive performance. We also
reviewed a variety of analytical strategies used in these stud-
ies, including univariate and multivariate analysis, meta-
analysis, pathway analysis, and interaction and network
analysis.
We summarized the major findings in Supplemental
Table 1, which includes all of the top 10 AD genes from the
AlzGenedatabase.Inparticular,severalofthesetopADgenes
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orated by ADNI imaging, fluid, and cognitive phenotypes.
ADNI imaging genetics studies also discovered novel find-
ings (e.g.,FRMD6) that were later replicated on different data
sets. Several genes (e.g., APOC1, FTO, GRIN2B, MAGI2,
andTOMM40) werediscoveredtobeassociatedwithmultiple
phenotypes by multiple studies using different approaches,
and these genes warrant further investigation and replication
on other data sets.
Pathway and network analysesofthese findingsimplicated
multipleinterestingbiologicalpathwaysaswellasstimulatory
and/or inhibitory relationships among these genes. It is note-
worthy that the majority of mapped pathways pointed to
neurodevelopmental rather than neurodegenerative processes.
In addition to standard SNP-based association studies, ADNI
geneticsdatahavealsobeenusedinseveralotherapplications,
includinginacomparativestudyofgenotypeimputation(Nho
et al. 2011), copy number variation analyses (Swaminathan
et al. 2011, 2012a, b), and for modeling disease progression
(Samtani et al. 2012).
ThesegeneticsresearchaccomplishmentsusingADNIdata
haveindicated the strong potential power of multidimensional
quantitativephenotypicdataforidentificationofnovelgenetic
variants and for investigation of disease mechanisms. This
should deepen our understanding of the biological pathways
involved in the disease trajectory and cognitive decline. The
availability of ADNI genetic data and multidimensional phe-
notypes from multiple imaging and biomarker modalities has
enabled new discovery of promising candidate genetic vari-
ants which may serve as targets for development of disease-
modifying agents or lead to enhanced diagnostic techniques
and biomarkers.
Strength and limitations of QTanalyses
Compared to case control status, quantitative traits can offer
increased statistical power and thus have reduced requirement
on sample size. This has been demonstrated by the discovery
of the FRMD6 gene (Fig. 2) mentioned earlier, as this gene
was identified in three ADNI imaging genetics studies
(Furney et al. 2011; Potkin et al. 2009a; Stein et al. 2010a)
with modest sample sizes (N≤1,004) and later validated by a
case control GWAS with a much larger sample (Hong et al.
2012)( N>12,500). On the other hand, the samples studied in
Table 2 Metacore pathway enrichment analysis results: 101 unique hit genes from ADNI papers are mapped to 124 Metacore object
(a) Enrichment by pathway maps: results with FDR p≤0.05 are shown.
# Pathway maps pValue FDR p Hit genes Total genes
1 Cell adhesion_Ephrin signaling 8.0E-05 0.018 4 45
2 Neurophysiological process_nNOS signaling in neuronal synapses 4.3E-04 0.048 3 29
3 Neurophysiological process_NMDA-dependent postsynaptic long-term
potentiation in CA1 hippocampal neurons
7.5E-04 0.050 4 80
4 Immune response_Alternative complement pathway 1.0E-03 0.050 3 39
5 Development_Neurotrophin family signaling 1.1E-03 0.050 3 40
(b) Enrichment by process networks: results with FDR p≤0.05 are shown.
# Process networks pValue FDR p Hit genes Total genes
1 Development_Neurogenesis_Axonal guidance 2.3E-04 0.020 8 230
2 Cell adhesion_Synaptic contact 3.4E-04 0.020 7 184
3 Development_Regulation of angiogenesis 1.1E-03 0.041 7 223
4 Cell adhesion_Attractive and repulsive receptors 1.6E-03 0.042 6 175
5 Development_Neurogenesis_Synaptogenesis 1.8E-03 0.042 6 180
(c) Enrichment by diseases: top 10 results are shown.
# Diseases pValue FDR p Hit genes Total genes
1 Alzheimer disease 2.7E-25 2.2E-22 45 1,244
2 Tauopathies 4.1E-25 2.2E-22 45 1,256
3 Mental disorders 9.3E-25 3.1E-22 68 3,388
4 Alzheimer disease, late onset 1.3E-24 3.1E-22 30 432
5 Psychiatry and psychology 1.4E-24 3.1E-22 68 3,412
6 Dementia 5.1E-22 8.0E-20 48 1,741
7 Delirium, dementia, amnestic, cognitive disorders 5.1E-22 8.0E-20 48 1,741
8 Neurodegenerative diseases 5.3E-21 7.3E-19 52 2,203
9 Nervous system diseases 2.8E-19 3.4E-17 81 6,022
10 Brain diseases 3.8E-18 4.1E-16 56 2,981
Top enrichment results by (a) pathway maps, (b) process network, and (c) diseases are shown
198 Brain Imaging and Behavior (2014) 8:183–207most QT analyses reviewed here are much smaller than
those used in large scale GWAS studies of AD. However,
these ADNI QT analyses not only identified associations
with top AD risk genes but also discovered potential
novel AD loci. This further demonstrates the increased
statistical power of QT analyses over case control analy-
ses. Another advantage of using QTs as intermediate phe-
notypes is that this strategy may have greater sensitivity in
clarifying the functional links related to the susceptibility
genes than diagnostic categories, as continuous measures
may more fully capture participants with subsyndromal
changes in pathologic markers of AD but which may
not meet MCI or AD diagnostic criteria, making it easier
to identify these genes.
Quantitative phenotypes in theory may achieve better
statistical power compared to disease susceptibility analy-
sis. The analysis, however, can be greatly influenced by
the relative sensitivities and accuracies of different pheno-
types (e.g., the 12-item ADAS-cog may not be as sensi-
tive to differences in cognition in prodromal AD).
Investigators have detected significant genetic markers
from relatively modest sample sets based on quantitative
traits (e.g., (Hu et al. 2011b)) yet the additional require-
ments in characterizing phenotypes (e.g., longitudinal
quantitative traits) have also made replication studies more
challenging. Improved statistical methods warrant further
investigation to minimize the number of these false posi-
tives while increasing sensitivity.
Next generation sequencing and convergent “omics”
Theultimategoalofanygeneticstudyofdiseaseistoimprove
the treatment of the disease. This end can be achieved most
directly through new therapeutics, but also via enhanced di-
agnostics and biomarkers for the improved targeting of pa-
tients and for use in therapeutic development. An increased
understanding of the genetic basis of any disease should lead
to the development of novel treatment options; of the roughly
500 human genes that have been successfully used as drug
targets, ~50 % are also linked to human diseases (Wang et al.
2012d). This is substantially higher than the proportion of
human genes in the genome that have been linked to disease
(roughly11%).Althoughitisimpossibletodefinitivelyprove
the reason for this association, the most likely explanation is
that in most cases a gene known to be causal for any given
diseaseis(almostbydefinition)inapathwaypossiblysuitable
for phenotypic modification to ameliorate the disease. Before
thiscan be attempted,the gene’s “druggability”, orhow easily
a drug against that gene class can be synthesized, needs to be
assessed.
Next generation sequencing (NGS) holds promise in this
area, especially when used in conjunction with GWAS data,
andideallywillassistinovercomingsomeofthelimitationsof
traditional GWAS approaches. Specifically, GWAS arrays
were designed to identify genetically homogeneous small
genomic regions and/or haplotypes (as opposed to individual
genes). This fact is not always appreciated by non-geneticists
Fig. 5 Chilibot analysis on 51 genes discovered from ADNI structural MRI
genetic studies.Chilibot(http://www.chilibot.net/)searchesPubMedabstracts
and constructs content-rich relationship networks among biological concepts,
genes, proteins, or drugs. We did a Chilibot query using 51 genes discovered
from ADNI structural MRI genetic studies. No relationship was reported for
five genes: BICD1, CAND1, GPCPD1, MAD2L2,a n dPRUNE2.W e
further filtered the graph by displaying only interactive relationships (i.e.,
excluding non-interactive relationship and abstract co-occurrence only).
Shown here is the resulting graph, containing 51−5=46 query terms. Note
that the 15 isolated genes shown in the bottom were included in the figure,
due to the existence of non-interactive relationship or abstract co-occurrence
only relationship (not shown) between them and some query genes. They
were shown here as isolated units because there was no interactive
relationship connecting them to other genes
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which genes have been implicated by certain GWAS. Upon
completion of a GWAS, significant SNPs are frequently iden-
tified as “hits” which are then assigned to the closest gene.
This strategy does not consider the fact that the SNP in
question may well be in tight linkage with another SNP or
genetic variant several to hundreds of kb away (Christoforou
et al. 2012). Students of the history of AD genetics research
may be less likely to make this error as the association of
APOE to AD acts as a case study for this phenomenon. The
APOE ε4allelehas unequivocallybeenlinkedtoAlzheimer’s
disease in over 100 studies (Bertram et al. 2007); however in
large AD GWAS the most significant SNPs have frequently
been located physically closer to other genes (APOC1 in (Naj
et al. 2011); TOMM40,a n dPVRL2 in (Harold et al. 2009))
than to APOE (though in tight linkage with the APOE ε4
allele). Jun et al. (2012) concluded “APOE alleles ε2, ε3, and
ε4 account for essentially all the inherited risk of AD associ-
ated with this region. Other variants including a poly-T track
in TOMM40 are not independent risk or AAO (Age At Onset)
loci”. The correct assignment of SNPs to genes remains an
issue if linkage is not taken into account during GWAS
analysis (Christoforou et al. 2012). Imputation can lessen this
effect to some extent, but not completely remove it.
Additional resolution is afforded by analyses probing for
association while conditioning on genotypes at known
disease-associated variants.
NGS (either whole genome sequencing or whole exome
sequencing)alleviatestheissueofbeingunabletopinpointthe
actual causal variants to some extent, and hopefully will
identify the next generation of drug targets for AD and other
diseases.Thereisgoodreasontobeoptimisticabouttheuseof
NGS in Alzheimer’s disease and specifically ADNI, based on
some early successes. The genetic profile of the ideal drug
target is relatively straightforward; loss of function and non-
sense variants in the gene would correlate perfectly with
protection from the disease in question (this is because it has
historically been easier to make antagonists of a gene than
agonists, but the reverse would hold true for gene classes for
which agonists can be developed). The population frequency
of the protective allele is less relevant; extremely rare alleles
can identify drug targets in the correct pathway as well as
commonones.Arecentexample (Jonssonetal.2012a)co me s
from the analysis of whole genome sequencing (WGS) of
roughly 1,800 Icelanders. Here, the A673T allele in the APP
gene appears to confer a roughly 4- to 8-fold reduction in the
risk of developing AD, possibly through a reduction in the
production of Aβ via less efficient cleavage of APP by
BACE1. Assuming these results are verified/replicated, they
would strongly suggest BACE1 inhibition would alter the
progression of AD if given at an early time point. In a similar
example, whole exome/whole genome sequencing in large
numbers of individuals led to the identification of the R47H
variantinTREM2 asariskfactorfor late-onsetAD(Guerreiro
et al. 2013;J o n s s o ne ta l .2012b). The identification of
TREM2 as an AD risk gene is notable in two respects. First,
with an odds ratio in the range of 3–5 over normal controls, if
confirmeditmaybeamongthelargesteffectsizesdetectedfor
any AD risk factor since the discovery of APOE ε4i n1 9 9 3 .
Secondly, as an immune receptor expressed on microglia and
linked to inflammation in the brain, this suggests new direc-
tions (or at least the elevation of certain candidate pathways)
for compound development. Regardless of whether either of
thesefindingsdirectlyleadstoatherapyforAD,itisemerging
that the application of NGS has already provided us with new
insights into the pathophysiology of AD and other neurode-
generative diseases. Early applications of whole exome se-
quencing in an extreme phenotype design in ADNI-1 data
have indicated variants associated with rate of progression of
hippocampal volume loss (Nho et al. 2013a, b).
The use of NGS data in conjunction with the ADNI mul-
timodal imaging, fluid and clinical phenotypes will likely be
extremely informative. While the discovery of a new risk
factor is interesting, the question as to whether the disease is
the same in carriers and non-carriers remains open. Is the
progression rate identical? Do the relative levels of disease
progression biomarkers differ? Do they change at different
rates with disease? And equally importantly, are there other
genetic factors that affect biomarker levels/activity even if
they do not affect the risk of developing the disease?
Controlling for variants such as these will be critical during
the design/implementation of phase II and III clinical trials.
One can argue that it would have been nearly impossible to
detect these variants (let alone know the extent of their effect
on biomarkers) without the combined analysis/intersection of
NGS data with ADNI imaging, fluid and/or cognitive bio-
marker (and/or detailed clinical) progression information.
Indeed, the most common genetic risk factor for AD, the
APOE epsilon 4 allele, increases not only the risk of AD but
also the rate of AD progression both in terms of cognitive
decline (e.g., (Stone et al. 2010)) and temporal lobe atrophy
(e.g., (Hua et al. 2010;R i s a c h e re ta l .2010;S a y k i ne ta l .
2010)). This makes APOE genotyping critical in AD disease
progression clinical trials in order to control for variance
among individuals over time. Further understanding of the
genetic variants influencing imaging, fluid and/or cognitive
biomarker levels and change will also increase the power and
accuracy of clinical trials.
The first, pioneering “Big Data” project for AD has been
launched to enable scientists to analyze the entire genome
sequence of over 800 individuals enrolled in the ADNI-GO/
2. Sequencing and initial QC have been completed and data
release is expected by fall of 2013. This ADNI whole genome
sequencing project, coupled with very rich multimodal ADNI
phenotypes, is expected to provide important new insights
into the genetic mechanisms of Alzheimer’s disease, which
200 Brain Imaging and Behavior (2014) 8:183–207in turn will impact the development of new diagnostic, ther-
apeutic and preventive approaches.
Application to clinical drug development
Use of genetic information within clinical drug development
primarily depends on effect size and predictive value of the
marker(s)totheassociatedendpoint.Todate,nogeneticfactor
beyond the APOE genotype has provided meaningful appli-
cation to the design and interpretation of clinical trials for
dementia and Alzheimer’s disease therapies. While AD case
control genetic studies provide drug developers with new
targets and pathways to pursue, the small individual effect
sizes of the risk variants may not be as useful as APOE for
direct application within clinical studies. However, genetic
studies of quantitative phenotypes and the convergence of
genetics with other biomarker endpoints are providing oppor-
tunities for new application of genetics to clinical trial design
beyond and in addition to APOE. Potential use of genetic
biomarkers in combination with other biomarker and clinical
datamayincludetheiruseintrialdesignenrichment(enrolling
mostlyorentirelybiomarker-positivesubjects),prospectiveor
post-hoc stratification (reduce or correct for heterogeneity),
and/or balancing or tailoring strategies. A recent finding from
ADNI, the first GWAS of amyloid PET (Ramanan et al.
2013), confirmed the role of APOE in amyloid burden on
[
18F]florbetapir PET but also detected a genome-wide signif-
icant role of the BCHE gene that codes for
butyrylcholinesterase, long studied as a constituent of plaque.
Together these loci accounted for 15 % of the variance in
amyloid deposition.
As the paradigm of patient selection for AD-modifying
candidate therapies shifts to an enrichment of the MCI popu-
lation, drug developers work to reduce costs of clinical trials
byaimingtodemonstrate responseovera shorter durationand
with fewer numbers of subjects. Many factors challenge the
success of this development model. Most stem from a lack of
accepted diagnostic and prognostic biomarkers of disease.
The work of several groups (Singh et al. 2012;W o l ze ta l .
2012;Y ue ta l .2012) demonstrate that use of novel statistical
and modeling approaches for stratification based on compos-
ite biomarker and cognitive rating scales can remove
unwanted heterogeneity and will likely improve statistical
power within the enrolled cohort. This type of approach can
provide a powerful tool for prospective enrichment or stratifi-
cation in clinical trials. To further increase predictive or prog-
nostic power of these algorithms, inclusion of additional ge-
netic biomarkers may be warranted. For example, if the
markers identified in age-at-onset studies can be replicated
in a prospective cohort, can these markers add additional
predictive power beyond APOE for MCI to AD progression
(Kamboh et al. 2011; Roses et al. 2010)? And while the effect
of APOE on observed variability in rate of AD progression is
atleastinpartdrivenbycarrierstatusoftheAPOE ε4 allele, if
the remaining heritability is identified will it be able to in-
crease power in models of prognosis (Potkin et al. 2009b, d;
Stone et al. 2010)? If validated, such models could help select
a clinical trial population with less heterogeneity, decreasing
trial duration and size.
Additionally, there is opportunity to incorporate genetic
findingsassociatedwithquantitativephenotypesintoanalyses
within early phase clinical development. Most early phase
programs use markers of pharmacodynamic response and
target engagement/specificity to demonstrate pharmacologic
response, including CSF, plasma, and imaging-based bio-
markers. Genetic markers identified as being associated with
longitudinal changes in these biomarkers could be assessed
withintheclinicalprogramsandusedascovariatesinanalyses
for post-hoc stratification or as enrichment criteria, decreasing
phenotypic variability within the trial cohort.
Among the most desired uses of genetic biomarker infor-
mationisinprospectivedefinitionofenhancedpharmacologic
response, or as a predictive pharmacogenetic marker. No
disease-modifying agent has yet made it into the marketplace,
but recent reports have shown hints of efficacy in subgroups
of individuals treated with drug candidates. APOE has been
assessed in most of these clinical trials, but it alone has not
shown correlation with subgroups of responders vs. non-
responders. It would be valuable to drug development pro-
grams to determine whether additional biomarkers are associ-
ated with response profiles, including genetic markers. A list
of plausible candidate genes could easily be assimilated based
on output from the studies of molecular heterogeneity, disease
pathways, endophenotypes, and quantitative phenotypes,
which could serve as testable hypotheses in an analysis of
drug response within phase 2 testing. These markers could
thenbeprospectivelydefinedandtestedforvalidityinphase3
clinical trials, potentially defining which individuals could
optimally be prescribed the drug.
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